Key result
Recent ACS management in prior CABG patients is linked to ~35% lower 30-day MACE.
Why the study?
It is unknown whether advances in management have improved prognosis in patients with prior CABG admitted with ACS over time.
Does modern management improve 30-day MACE and 1-year mortality in patients with prior CABG admitted with ACS compared to earlier management?
Cohort (n=15,152)
Yes
Does modern management improve 30-day MACE and 1-year mortality in patients with prior CABG admitted with ACS compared to earlier management?
Absolute Event Rate: 12.4% vs 19.1%
p-value: p=0.001
Despite improvements in short-term outcomes and increased use of guideline-directed therapies, 1-year mortality for patients with prior CABG admitted with ACS has not improved over time.
Unchanged 1-year mortality in post-CABG ACS despite better short-term care signals need for targeted strategies; leaves open optimal long-term interventions.
BACKGROUND: Patients with prior coronary artery bypass graft surgery (CABG) are at increased risk for recurrent cardiovascular ischaemic events. Advances in management have improved prognosis of patients with acute coronary syndrome (ACS), yet it is not known whether similar trends exist in patients with prior CABG. AIM: Examine temporal trends in the prevalence, treatment and clinical outcomes of patients with prior CABG admitted with ACS. METHODS: Time-dependent analysis of patients with or without prior CABG admitted with an ACS who enrolled in the ACS Israeli Surveys between 2000 and 2016. Surveys were divided into early (2000-2008) and late (2010-2016) time periods. Outcomes included 30 days major adverse cardiac events (30d MACE) (death, myocardial infarction, stroke, unstable angina, stent thrombosis, urgent revascularisation) and 1-year mortality. RESULTS: Among 15 152 patients with ACS, 1506 (9.9%) had a prior CABG. Patients with prior CABG were older (69 vs 63 years), had more comorbidities and presented more with non-ST elevation-ACS (82% vs 51%). Between time periods, utilisation of antiplatelets, statins and percutaneous interventions significantly increased in both groups (p<0.001 for each). The rate of 30d MACE decreased in patients with (19.1%-12.4%, p=0.001) and without (17.4%-9.5%, p<0.001) prior CABG. However, 1-year mortality decreased only in patients without prior CABG (10.5% vs 7.4%, p<0.001) and remained unchanged in patients with prior CABG. Results were consistent after propensity matching. CONCLUSIONS: Despite an improvement in the management and prognosis of patients with ACS in the last decade, the rate of 1-year mortality of patients with prior CABG admitted with an ACS remained unchanged.
No takes yet. Share an insight, caveat, or question.
Marcuschamer et al. (2021) conducted a cohort in Acute coronary syndrome (n=15,152). Late time period (2010-2016) vs. Early time period (2000-2008) was evaluated on 30 days major adverse cardiac events (30d MACE) in patients with prior CABG (p=0.001). In patients with prior CABG admitted with ACS, 30-day MACE decreased from 19.1% in 2000-2008 to 12.4% in 2010-2016 (p=0.001), but 1-year mortality remained unchanged.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: